ABOUT
Rheumatologist & Immunologist
Guillermo J. Valenzuela, MD, F.A.C.R.
Dr. Guillermo Valenzuela, MD, stands at the forefront of innovation and excellence in the field of rheumatology and immunology. As a distinguished rheumatologist, Dr. Valenzuela serves as the past president of the Florida Society of Rheumatology and holds the esteemed position of medical director at Integral Rheumatology & Immunology Specialists and IRIS Research and Development. With a profound commitment to advancing medical knowledge and patient care, he is dedicated to pioneering breakthrough treatments and protocols for a spectrum of autoimmune disorders.
Guillermo J. Valenzuela, MD, F.A.C.R.
Rheumatologist & Immunologist
Dr. Valenzuela’s illustrious career is underscored by an impressive academic pedigree. He earned his medical degree with honors from the prestigious University of Buenos Aires in Argentina, followed by comprehensive training in internal medicine at New York Medical College.
Driven by an insatiable thirst for knowledge, he pursued post-doctoral fellowships in Clinical Immunology and Rheumatology & Clinical Immunology at Cornell University Medical College in New York, solidifying his expertise in these specialized fields.
As a beacon of excellence in clinical practice, Dr. Valenzuela oversees patient care at Integral Rheumatology & Immunology Specialists, where he delivers compassionate and cutting-edge treatments tailored to the unique needs of each individual.
Concurrently, his leadership at IRIS Research and Development underscores his unwavering commitment to advancing the frontiers of medical science. Dr. Valenzuela spearheads pioneering clinical trials on emerging therapies for rheumatic diseases, leveraging his expertise to drive transformative advancements in patient care.
Dr. Valenzuela’s contributions extend beyond the realm of clinical practice, as he is a prolific author of scientific publications and a sought-after lecturer on both national and international platforms. His unwavering dedication to advancing medical knowledge and patient outcomes has earned him widespread recognition and admiration within the medical community. In every endeavor, Dr. Valenzuela exemplifies the highest standards of professionalism, integrity, and compassion. He is a true visionary whose tireless pursuit of excellence continues to elevate the field of rheumatology and inspire future generations of medical professionals.
- A randomized, controlled pragmatic phase 3B/4 study of baricitinib in patients with rheumatoid arthritis.
- A randomized, double-blind, placebo-controlled study of ALPN-101 in systemic lupus erythematosus (SLE).
- A multicenter randomized double-blind placebo-controlled phase 3 study to evaluate the efficacy and safety of anifrolumab in adult patients with active profilerative lupus nephritis.
- A randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patients with diffuse cutaneos systemic sclerosis.
- A multicenter, open-label extension trial to evaluate the efficacy, safety and tolerability of HZN-825 in patients with diffuse cutaneous systemic sclerosis.
- A randomized placebo-controlled study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus.
- A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus.
- A phase 2 randomized, double-blind, placebo-controlled efficacy and safety study of VIB7734 for the treatment of moderate to severely active systemic lupus erythematosus.
- A phase 3B, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of guselkumab administered subcutaneously in participants with active psoriatic arthritis who had an inadequate response and/or intolerance to one prior anti-tumor necrosis factor a agent.
- A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Oral brepocitinib in adults with dermatomyositis.
- A phase 4, multicenter, open-label, infusion duration study to assess safety, tolerability and efficacy of pegloticase administered with a shorter infusion duration in subjects with uncontrolled gout receiving methotrexate.
- A multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the efficacy and safety of daxdilimab in adult participants with active proliferative Lupus Nephritis.
- A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of cenerimod ni adult subjects with moderate-to severe systemic lupus Erythematosus (SLE) on top of background therapy.
- A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of nipocalimab in participants with active idiopathic inflammatory myopathies.
- A phase 2, randomized, placebo-controlled, double-blind, parallel-group, efficacy and safety study of bi 685509 ni adults with early progressive diffuse cutaneous systemic sclerosis.